Cookie policy: This site uses cookies to simplify and improve your usage and experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information on how we use and manage cookies please take a look at our privacy and cookie policies. Your privacy is important to us and our policy is to neither share nor sell your personal information to any external organisation or party; nor to use behavioural analysis for advertising to you.

Hot papers in Alzheimer's disease research

Hot papers in Alzheimer’s disease research
Data provided by Thomson Reuters from its Essential Science Indicators database, 2008-2010
 %3Cb%3EPaper%3C/b%3E %3Cbr /%3EAuthor(s), JournalCitations
1%3Cb%3EGenome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease%3C/b%3E %3Cbr /%3EDenise Harold, Richard Abraham, Paul Hollingworth et al %3Cbr /%3E%3Cem%3ENature Genetics%3C/em%3E, 41 (10): 1088-1093, October 2009 111
2%3Cb%3EGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease%3C/b%3E %3Cbr /%3EJean-Charles Lambert, Simon Heath, Gael Even et al (European Alzheimer’s Disease Initiative) %3Cbr /%3E%3Cem%3ENature Genetics%3C/em%3E, 41 (10): 1094-1099, October 2009109
3%3Cb%3ECyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease%3C/b%3E %3Cbr /%3EHeng Du, Lan Guo, Fang Fang et al %3Cbr /%3E%3Ci%3ENature Medicine%3C/i%3E, 14 (10): 1097-1105, October 200893
4%3Cb%3ENeuronal calcium mishandling and the pathogenesis of Alzheimer’s disease%3C/b%3E %3Cbr /%3EIlya Bezprozvanny and Mark P. Mattson %3Cbr /%3E%3Ci%3ETrends in Neurosciences%3C/i%3E, 31 (9): 454-463, 1 September 200891
5%3Cb%3EThirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses%3C/b%3E %3Cbr /%3ELars Bertram and Rudolph E. Tanzi %3Cbr /%3E%3Ci%3ENature Reviews Neuroscience%3C/i%3E, 9 (10): 768-778, October 200889
6%3Cb%3ECerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects%3C/b%3E %3Cbr /%3ELeslie M. Shaw, Hugo Vanderstichele, Malgorzata Knapik-Czajka et al (Alzheimer’s Disease Neuroimaging Initiative) %3Cbr /%3E%3Ci%3EAnnals of Neurology%3C/i%3E, 65 (4): 403-413, April 2009 85
7%3Cb%3ECSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment%3C/b%3E %3Cbr /%3ENiklas Mattsson, Henrik Zetterberg, Oskar Hansson et al %3Cbr /%3E%3Ci%3EJournal of the American Medical Association%3C/i%3E, 302 (4): 385-393, 22/29 July 200962
8%3Cb%3EApolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy%3C/b%3E %3Cbr /%3EGuojun Bu %3Cbr /%3E%3Ci%3ENature Reviews Neuroscience%3C/i%3E, 10 (5): 333-334, May 2009 55
9%3Cb%3EThe role of Apolipoprotein E in Alzheimer’s disease%3C/b%3E %3Cbr /%3EJungsu Kim, Jacob M. Basak and David M. Holtzman %3Cbr /%3E%3Ci%3ENeuron%3C/i%3E, 63 (3): 287-303, 13 August 2009 52
10%3Cb%3EImpaired balance of mitochondrial fission and fusion in Alzheimer’s disease%3C/b%3E %3Cbr /%3EXinglong Wang, Bo Su, Hyoung-gon Lee et al %3Cbr /%3E%3Ci%3EJournal of Neuroscience%3C/i%3E, 29 (28): 9090-9103, 15 July 200950

Over the past 20 years, the number of science and social sciences articles published in the journals indexed by Thomson Reuters for its Web of Science database doubled, from 900,000 to 1.8 million. In the same period, papers dealing with Alzheimer’s disease more than quadrupled in number, from about 2,200 in 1990 to 8,900 in 2009. Even so, one may wonder if research on this disease is being pursued and funded as much as it should be considering other numbers that characterise the condition: as of 2010, 36 million people worldwide suffer with dementia of which Alzheimer’s disease is a major part; $600 billion a year is spent in caring for these patients; and this figure amounts to some 1 per cent of the world’s gross domestic product (see World Alzheimer’s Report 2010, published by Alzheimer’s Disease International). Earlier this year, the Health Economics Research Centre of the University of Oxford, in a study prepared for the Alzheimer’s Research Trust, reported that in the UK, cancer research receives 12 times more funding than dementia research; at the same time, the costs of dementia in the country are twice that for cancer care and treatment (see the trust’s Dementia 2010 report).

Thomson Reuters identified the papers listed above as current hot papers in Alzheimer’s disease research. Hot papers are two years old or younger and have been cited at a high rate (top 0.1 per cent), considering their field and time of publication (analysed in bimonthly publication windows). The oldest article in the group appeared in September 2008 and the newest ones were published in October 2009. These most recent two, ranking first and second by total citations, report three new susceptibility loci (CLU, PICALM, CR1) for late-onset Alzheimer’s disease. Two other papers, ranked sixth and seventh, investigate the use of biomarkers in cerebrospinal fluid to detect incipient Alzheimer’s disease in persons with mild cognitive impairment. This topic is a particularly active area in Alzheimer’s disease research, demonstrated by the publication of more than 300 reports so far in 2010.

For more information on Thomson Reuters Essential Science Indicators, see http://science.thomsonreuters.com/products/esi

  • Print
  • Share
  • Save
  • Print
  • Share
  • Save
Jobs